Start-up LinKinVax and Gustave Roussy enter into a collaboration to conduct a Phase I/IIa HPV.DCVax clinical trial for the treatment of patients with human papillomavirus (HPV) associated oropharyngeal cancer

Created in 2020 and led by two internationally renowned personalities who combine medical, industrial and business expertise, André-Jacques Auberton-Hervé, Honorary Chairman and founder of SOITEC, and Professor Yves Levy, MD, PhD, immunologist, Director of the Vaccine Research Institute (VRI/INSERM/UPEC) and head of the “Physiopathology and immunotherapies in HIV infection” team at the IMRB, the start-up LinKinVax is developing an innovative protein vaccine platform to accelerate the availability of vaccines based on the work of VRI.


The objectives of the study, sponsored by Gustave Roussy, are to demonstrate the safety and immunogenicity of the CD40HVac oncogenic HPV vaccine candidate in combination with the Poly-ICLC adjuvant (Hiltonol®) in patients with head and neck cancer and to determine the recommended Phase 2 dose based on the safety profile of the vaccine candidate and its ability to induce immune responses. Several exploratory objectives are also planned to estimate progression-free survival and overall survival.


LinKinVax is developing CD40HVac, a therapeutic vaccine against HPV-associated malignancies, based on a novel technology that directly targets dendritic cells (DCs), which play a crucial role in immunity by stimulating and regulating immune responses.


Read the full press release LinKinVax